Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Medtronic plcNYSE: MDT
Research & Development · Q1 FY2027 · quarter ended Jul 2026
Research & development grows in line with its trailing trend
Q1 FY2027 research & development of $771M rose 6.2% year over year, ahead of the +4.9% change in trailing-twelve-month research & development. Sequentially, it rose 14.9% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Research & development amounted to 7.9% of revenue in FY2026, down 0.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6.2% holds above the trailing-twelve-month pace of +4.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 2.87B USD
- Year-over-year change
- +5.2%
- 4-year CAGR
- +1.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 2.87B | +5.2% |
| FY2025 | 2025-04-25 | 2.73B | -0.1% |
| FY2024 | 2024-04-26 | 2.74B | +1.4% |
| FY2023 | 2023-04-28 | 2.7B | -1.8% |
| FY2022 | 2022-04-29 | 2.75B | — |
Research & Development vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.9% is the 5th highest of 9, against a peer median of +6.7%.
- Research & development amounts to 7.8% of revenue for MDT, versus a peer median of 10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.92B USD | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B USD | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | €1.72B EUR | -2.6% | -6.7% | 9.7% | |
| LTM Jun 2026 | $1.66B USD | +10.1% | +8.8% | 6.4% | |
| LTM Jun 2026 | $1.09B USD | +3.3% | +4.5% | 16.7% | |
| LTM Jun 2026 | $442.9M USD | -0.2% | +4.1% | 5.2% | |
| LTM Sep 2026 | $202.57M USD | +14.5% | +6.0% | 13.4% | |
| LTM Jun 2026 | $92.25M USD | +1.9% | +4.2% | 6.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M USD | +24.4% | +57.8% | 3788.3% |
| Peer median (excluding MDT) | — | +6.7% | +5.3% | 10.0% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Revenue | 31.69B | 31.23B | 32.36B | 33.54B | 36.36B |
| Cost of Revenue | 10.15B | 10.72B | 11.22B | 11.63B | 12.72B |
| Gross Profit | 21.54B | 20.51B | 21.15B | 21.91B | 23.64B |
| Gross Margin | 68.0% | 65.7% | 65.3% | 65.3% | 65.0% |
| Research & Development | 2.75B | 2.7B | 2.74B | 2.73B | 2.87B |
| Selling, General & Admin | 10.29B | 10.42B | 10.74B | 10.85B | 11.78B |
| Operating Expenses | 15.79B | 15.02B | 16B | 15.95B | 17.18B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| EBITDA | 8.78B | 8.7B | 8.2B | 9.22B | 9.81B |
| EBITDA Margin | 27.7% | 27.9% | 25.3% | 27.5% | 27.0% |
| Operating Income | 5.75B | 5.49B | 5.14B | 5.96B | 6.47B |
| Operating Margin | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 553M | 636M | 719M | 729M | 715M |
| Other Income / Expenses | (235M) | (121M) | (307M) | (327M) | (331M) |
| Income Before Tax | 5.52B | 5.36B | 4.84B | 5.63B | 6.14B |
| Pre-Tax Margin | 17.4% | 17.2% | 14.9% | 16.8% | 16.9% |
| Income Tax Expense | 456M | 1.58B | 1.13B | 936M | 1.3B |
| Net Income | 5.04B | 3.76B | 3.68B | 4.66B | 4.8B |
| Net Margin | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| EPS (Basic) | 3.75 | 2.83 | 2.77 | 3.63 | 3.75 |
| EPS (Diluted) | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 |
| Weighted Avg Shares | 1.34B | 1.33B | 1.33B | 1.29B | 1.28B |
| Weighted Avg Shares (Diluted) | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.